PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23056499-0	2012	AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.	AZD 1480	0-7	ret proto-oncogene	Homo sapiens	43-46	
23056499-3	2012	Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET.	AZD 1480	53-60	ret proto-oncogene	Homo sapiens	147-150	
23056499-9	2012	In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells).	AZD 1480	15-22	ret proto-oncogene	Homo sapiens	86-89	
23056499-9	2012	In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells).	AZD 1480	15-22	ret proto-oncogene	Homo sapiens	140-143	
23056499-10	2012	Thus, AZD1480 should be considered as a therapeutic agent for the treatment of RET- activated thyroid cancers.	AZD 1480	6-13	ret proto-oncogene	Homo sapiens	79-82	
29312610-0	2017	Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.	AZD 1480	84-91	ret proto-oncogene	Homo sapiens	46-49	
29312610-5	2017	We demonstrate that AZD1480 inhibits ALK, LTK, FGFR1-3, RET and TRKA-C kinases and uncover a physical basis of this specificity.	AZD 1480	20-27	ret proto-oncogene	Homo sapiens	56-59